Tango Therapeutics, Inc. (TNGX)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $3.67B
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Latest financial period: June 30, 2026
Filed with the SEC: August 11, 2026
Estimated earnings date: November 3, 2026
Profit #1385 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 4.9% | 4.1% | 4.3% | 3.7% |
Growth #313 of 1484 companies
Payout #1117 of 1484 companies
Safety #772 of 1484 companies
Price #1403 of 1484 companies
